Single-cell and clonal analysis of AL amyloidosis plasma cells and their bone marrow microenvironment
Abstract
Abstract AL amyloidosis is a disorder characterized by expansion of clonal plasma cells in the bone marrow and distant end organ damage mediated by misfolded immunoglobulin free light chains. There are currently limited data regarding the functional characteristics of AL amyloidosis plasma cells and their surrounding bone marrow microenvironment. We performed 5’ single-cell RNA sequencing on newly diagnosed, treatment-naïve patients with AL amyloidosis and healthy subjects. We identified generalized suppression of normal bone marrow hematopoiesis with distinct expansion of monocytes and subsets of CD4+ T cells in patients with AL amyloidosis. We detected significant transcriptional changes broadly occurring among immune cells with increased tumor necrosis factor-α signaling and interferon response accompanied by increased inflammatory response in bone marrow plasma, as measured via quantitative proteomics with specific elevation of costimulatory molecule soluble CD276 (sB7-H3). A transcriptionally distinct population of nonmalignant plasma cells was disproportionately expanded in patients with AL amyloidosis and characterized by increased expression of CRIP1. Finally, clonal AL amyloidosis plasma cells were identified based on their unique variable-diversity-joining. rearrangement and showed increased expression of genes involved in proteostasis when compared with autologous, polyclonal plasma cells. Interpatient transcriptional heterogeneity was evident, with transcriptional states reflective of common genomic translocations easily identifiable. This study defines the transcriptional characteristics of AL amyloidosis plasma cells and their surrounding bone marrow microenvironment with identification of altered genes previously involved in the pathogenesis of other protein deposition disorders. Our data provide the rationale for functional validations of these genes in future studies.
Article Details
Authors (25)
Nicolas A. Gort-Freitas
1Department of Systems Biology, Blavatnik Institute, Harvard Medical School, Boston, MA
Maria Moscvin
2Division of Hematology, Brigham and Women’s Hospital, Boston, MA
Matteo C. Da Vià
3Hematology Section, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
Francesca Lazzaroni
2Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
Alice Nevone
4Department of Molecular Medicine, University of Pavia, Pavia, Italy
Sam Sadigh
Brigham and Women’s Hospital
Samuel Boullt
2Division of Hematology, Brigham and Women’s Hospital, Boston, MA
Benjamin Evans
2Division of Hematology, Brigham and Women’s Hospital, Boston, MA
Tianzeng Chen
Laboratory of Atmospheric Environment and Pollution Control, Research Center for Eco-Environmental Sciences
Tanya Karagiannis
7Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA
Albert Tai
9Department of Immunology, Tufts University School of Medicine, Boston, MA
Sean Rowell
10Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
Srinidhi Raghav
10Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
Antonia F. Chen
University of Texas Southwestern Medical Center, Dallas
Jacob P. Laubach
Caitlin Edwards
6Department of Pathology, Brigham and Women’s Hospital, Boston, MA
Jon C. Aster
Zizhang Sheng
Joao A. Paulo
Chi N. Chan
15Tissue Technologies Unit, Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Mario Nuvolone
Department of Molecular Medicine, University of Pavia, Italy (M.N., G.D.S., G.P.).
Niccolò Bolli
1Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
Raymond L. Comenzo
Tufts Medicine Myeloma and Amyloid Program Tufts Medical Center Boston Massachusetts USA
Allon M. Klein
Giada Bianchi